Mineralys first patient dosed in ADVANCE-HTN pivotal trial of lorundrostat for hypertension

Mineralys Therapeutics, Inc.

ADVANCE-HTN trial to enroll up to 300 adults with uncontrolled or resistant hypertension.
Primary endpoint: change in systolic BP vs placebo after 12 weeks (24-hr ambulatory monitoring).
Topline data from ADVANCE-HTN expected in first half of 2024.
Second pivotal Phase 3 trial to begin enrolling H2 2023, data anticipated mid-2025.
Phase 2 CKD trial for lorundrostat expected to start mid-2023, topline data H1 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.